Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2003-09-23
2009-08-18
Parkin, J. S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S188100
Reexamination Certificate
active
07575750
ABSTRACT:
This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
REFERENCES:
patent: 3719667 (1973-03-01), Gutowski
patent: 3840556 (1974-10-01), Kukolja
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5840697 (1998-11-01), Blondelle et al.
patent: 6258782 (2001-07-01), Barney et al.
patent: 6268479 (2001-07-01), Stern et al.
patent: 6281331 (2001-08-01), Kang et al.
patent: WO 99/59615 (1999-11-01), None
patent: WO 00/69902 (2000-05-01), None
patent: WO 00/69902 (2000-11-01), None
patent: WO 00/69911 (2000-11-01), None
patent: WO 00/70665 (2000-11-01), None
T.W. Green, “Protection for the Carboxyl Group,” Chapter 5, Protective Groups in Organic Synthesis, published by John Wiley & Sons, New York, USA, 1981, pp. 152-192.
Creamer et al., “α-Helix-Forming Propensities in Peptides and Proteins,” Proteins: Structure, Function, and Genetics 19:85-97 (1994), Wiley-Liss, Inc.
Chan et al., “Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target,” Proc. Natl. Acad. Sci. USA, vol. 95, pp. 15613-15617, Dec. 1998, The National Academy of Sciences.
Malashkevich et al., “Crystal structure of the simian immunodeficiency virus(SIV)gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides,” Proc. Natl. Acad. Sci USA, vol. 95, pp. 9134-9139, Aug. 1998, The National Academy of Sciences.
Wild et al., “Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection,” Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9770-9774, Oct. 1994, The National Academy of Sciences.
Stehle et al., “The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats,” Anti-Cancer Drugs, 1997, vol. 8, pp. 677-685, Rapid Science Publishers.
Jiang He
Xie Dong
Frontiers Biotechnologies Col, Ltd.
Hunton & Williams LLP
Parkin J. S.
LandOfFree
Human immunodeficiency virus (HIV) gp41 peptide derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human immunodeficiency virus (HIV) gp41 peptide derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human immunodeficiency virus (HIV) gp41 peptide derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4129157